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Abstract
Background. Subthalamic deep brain stimulation (STN-DBS) is an effective treatment for selected Parkinson’s disease (PD)
patients. Gait characteristics are often altered after surgery, but quantitative therapeutic effects are poorly described. Objective.
The goal of this study was to systematically investigate modiﬁcations in asymmetry and dyscoordination of gait 6 months
postoperatively in patients with PD and compare the outcomes with preoperative baseline and to asymptomatic controls
without PD. Methods. A convenience sample of thirty-two patients with PD (19 with postural instability and gait disorder (PIGD)
type and 13 with tremor dominant disease) and 51 asymptomatic controls participated. Parkinson patients were tested prior to
the surgery in both OFF and ON medication states, and 6-months postoperatively in the ON stimulation condition. Movement
Disorder Society-Uniﬁed Parkinson’s Disease Rating Scale (MDS-UPDRS) I to IV and medication were compared to preoperative conditions. Asymmetry ratios, phase coordination index, and walking speed were assessed. Results. MDS-UPDRS I to
IV at 6 months improved signiﬁcantly, and levodopa equivalent daily dosages signiﬁcantly decreased. STN-DBS increased step
time asymmetry (hedges’ g effect sizes [95% conﬁdence interval] between pre- and post-surgery: .27 [-.13, .73]) and phase
coordination index (.29 [-.08, .67]). These effects were higher in the PIGD subgroup than the tremor dominant (step time
asymmetry: .38 [-.06, .90] vs .09 [-.83, 1.0] and phase coordination index: .39 [-.04, .84] vs .13 [-.76, .96]). Conclusions. This study
provides objective evidence of how STN-DBS increases asymmetry and dyscoordination of gait in patients with PD and suggests
motor subtypes-associated differences in the treatment response.
Keywords
gait symmetry, gait coordination, Parkinson’s disease, deep brain stimulation, basal ganglia

Introduction
Deep brain stimulation (DBS) that targets the subthalamic
nucleus (STN) of the basal ganglia has shown therapeutic
potential as an adjunct to pharmacotherapy for alleviating
motor symptoms of Parkinson’s disease (PD).1 While the
treatment appears effective in providing relief to the cardinal
motor deﬁciencies of the disease (bradykinesia/akinesia, tremor,
and rigidity), the outcomes on gait remain inconclusive.2,3
Evidence from long-term follow-up studies has shown that
certain aspects of gait function improve initially postoperatively
but then progressively worsen.4,5 It is estimated that gait deterioration occurs in about 25% of patients with PD (PwPD)
after subthalamic deep brain stimulation (STN-DBS)6 and a
subset of them may experience fall.7,8 The causes of insufﬁcient
gait outcome are not well understood, and this is largely due to
the paucity of objective investigations of gait characteristics in
PwPD undergoing DBS.9

Most long-term studies have investigated gait outcomes
using Movement Disorder Society-Uniﬁed Parkinson’s Disease Rating Scale (MDS-UPDRS-III) clinical motor scores.10
Although MDS-UPDRS-III is an internationally accepted and
widely used clinical assessment scale (rapidly administered to
measure clinically relevant outcomes), it only includes very
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few evaluations on walking ability or gait. The subtleties involved with controlling gait such as symmetry, variability, and
coordination are important but remain unevaluated in standardized MDS-UPDRS-III assessments. Moreover, such objective gait characteristics could be used as biomarkers for
reliable selection of DBS candidates,11 adaptive stimulation,12
and assessing treatment endpoints thereafter.13
One of the deﬁning symptomatic gait characteristics of
PwPD is hypokinesia (slowness of walking) accompanied by
small and variable step length.14 The effects of STN-DBS on
walking speed and step length were investigated initially by
Allert and co-workers15 in a pre-post study (follow-up assessments after 3 months) on 8 PwPD with severe disability.
They found a signiﬁcant increase in step length as well as gait
velocity and subsequent studies have been able to corroborate
this ﬁnding in both ON–OFF stimulation as well as pre-post
designs.16-18 Previous evidence also suggests beneﬁcial effect
of STN-DBS on hip, knee, and ankle joint range of
motions.11,16 However, varying reports on other important
gait parameters (e.g., cadence and dual limb support time) and
a general lack of long-term objective follow-ups preclude
concrete conclusions for the alleviation of gait deﬁcits using
STN-DBS in PwPD.2,3,9
One pertinent investigation of STN-DBS in PwPD that has
not been adequately described is the effects on asymmetry and
dyscoordination of gait. This is particularly important because
asymmetrical gait characteristics are often the ﬁrst motor
symptoms seen in these populations,19 demonstrated as a
clinical marker of prodromal PD20 and discriminate distinct
motor stages of PwPD.21 In clinics, the practice of using bilateral DBS lead implantation is quite common, with surgical
targets and stimulation settings often optimized to achieve best
effects on upper limb tremor, rigidity etc., while minimizing
relevant adverse effects (can be referred to as ‘clinically determined settings’, evaluated using MDS-UPDRS I to IV).
However, despite the prevalence of asymmetrical stimulation
settings for bilateral DBS, asymmetry, particularly in the lower
limbs has been shown to often persist15 or increase at 6 months
after surgery11 for unknown reasons. Importantly, insufﬁcient
attention to asymmetry may be responsible for adverse events
including freezing of gait (FOG) and fall episodes in a subgroup of patients after the surgery.22-24
As mobility and functional gait are critical for health and
quality of life, an in-depth account of stimulation to gait and
clinical outcome relations seems then essential for developing
a comprehensive DBS therapy in PwPD. The current study is
part of a larger research project designed to investigate the
predictive value of objective gait measures for DBS therapy
outcomes in PwPD. In an exploratory study design, we
systematically investigated alterations in our primary outcome: MDS-UPDRS III and our secondary measures: gait
asymmetry, dyscoordination, and walking speed 6 months
post-DBS in PwPD. We tested the hypothesis that PD motor
subtypes, including tremor dominant (TD), postural instability and gait disorder (PIGD), and indeterminate (neither
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tremor nor postural instability as deﬁning features) types
would show distinct therapeutic effects on clinical and gait
outcomes.

Methods
Study Design
A convenience sample of thirty-two PwPD (excluding dropouts, 26 men, 6 women, with mean age 60.2 (SD 9.6) years, PD
duration: 10.3 (5.0) years, preoperative MDS-UPDRS-III in
OFF medication: 39.97 (12.51), and preoperative Hoehn and
Yahr scale in OFF medication: 2 (1–3) denotes mild or early
PD, Table 1 and Supplementary Table 1) were recruited at the
University Hospital of Zurich. In addition, 51 asymptomatic
controls without PD (22 men, 29 women, and mean age 66.6
(10.7) years) participated voluntarily (in response to ﬂyers and
newspaper advertisements) in this study. Inclusion criteria for
the control participants consisted of the following: 40 to
90 years of age, free from neurological, psychiatric, and orthopedic disorders and were able to independently walk for
10 minutes. The study was approved (approval no: 201500141) by Zurich Cantonal Ethics Commission and carried
out in accordance with the Declaration of Helsinki, the
guidelines of Good Clinical Practice, and the Swiss regulatory authority’s requirements. The subjects all provided
written, informed consent prior to participation. The detailed surgical protocol and postoperative management of
patients are provided in Supplementary Methods 1. Stimulation parameters are presented in Supplementary Table 2.

Data Collection
Clinical Assessment. Motor symptoms were assessed using
MDS-UPDRS III, evaluated twice pre-surgery—in the ON
and OFF medication conditions (as part of the levodopa
challenge test used to screen DBS candidates that demonstrates levodopa responsiveness25)—as well as once around 6
months post-surgery in the medication and stimulation ON
condition. MDS-UPDRS I (non-motor symptoms), II (activities of daily living), and IV (dyskinesias and motor
ﬂuctuations) were also performed once (OFF medication
condition) before surgery and once after surgery. In addition,
dopaminergic treatment was recorded as levodopa equivalent
daily dose. The clinical subtypes of PwPD such as TD, PIGD,
and indeterminate types were also identiﬁed.26 The predominant symptom side was identiﬁed by medical history and
during the clinical examination and substantiated using the
MDS-UPDRS asymmetry: difference between left and right
motor scores of MDS-UPDRS Part III (items 3.3–3.8 and
3.15–3.17).27
Objective Gait Measures. PwPD were tested prior to surgery in
the medication ON state, and once around 6 months after the
surgery in the ON medication and ON stimulation condition.
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Table 1. Baseline and Longitudinal Demographics and Clinical Characteristics.
Characteristic

Healthy Controls
(N = 51)

PwPD Pre-DBS
(N = 32)

PwPD Post-DBS
(N = 32)

Healthy Controls vs PwPD
Pre-DBS P-value

Age (years)
Male/female
Weight (kg)
Height (cm)
Age of onset of disease (yr)
Disease duration (yr)
H&Y stage
MDS-UPDRS-based clinical subtypes

66.6 (10.7)
22/29
68.1 (12.2)
168.9 (8.8)
-

60.9 (9.7)
27/5
78.6 (11.7)
175.9 (6.7)
2 (1–2.5)
-

<
<
<
<
-

Symptom side

-

-

-

Handedness

-

60.2 (9.6)
27/5
77.0 (13.7)
176.0 (6.8)
49.9 (9.3)
10.3 (5.0)
2 (1–3)
TD (N = 13)
PIGD (N = 19)
Indeterminate (N = 0)
Left-sided symptom onset
(N = 18)
Right-sided symptom onset
(N = 14)
Right handedness (N = 30)
Forced right handedness
(N = 2)

-

-

.01
.01
.01
.01

Values expressed as mean (standard deviation) or median (lower limit–higher limit).
Differences in age, weight, and height were assessed using t-tests. Difference in no of male/female participants was assessed using a chi-square test. Statistical
signiﬁcance was determined at P < .01.; Abbreviations: MDS-UPDRS, Movement Disorder Society-Uniﬁed Parkinson’s Disease Rating Scale; PwPD, patients with
Parkinson’s disease; DBS, deep brain stimulation; H&Y, Hoehn and Yahr; TD, tremor dominant; PIGD, postural instability and gait disorder.

Here, most subjects in the post-condition were still taking a
clinically adapted dose of medication (Supplementary
Methods 2), except for 3 subjects that were completely
OFF medication. The evaluators who performed the gait
analysis were not blinded to the group status (e.g., asymptomatic controls vs PwPD). All participants were instructed to
walk (barefoot, self-selected speed, and without any aid or
assistance) continuously for 10 minutes in an eight-shape
around 2 marked spots 10 m apart. The use of an “8-walk”
protocol allows the collection of a high number of consecutive gait cycles during overground walking that is necessary
in order to reliably assess gait performance.28 A threedimensional motion capture camera system (10 cameras;
61 markers; 100 Hz; Vicon Nexus, version 2.3/2.8.2, Oxford
Metrics, United Kingdom) was used to record the movements. Before each data collection, a calibration routine was
performed across the entire capture volume (calibration error
threshold set at 0.5 mm). In addition, we followed the
published recommendations for minimizing error associated
with marker placement.29 The trajectories of the heel (calcaneus), toe (metatarsal head III), and sacrum (midpoint
between left and right posterior superior iliac spines) markers
were used to extract gait kinematics.

Data Analyses
Pre-processing. The raw kinematic data (from 2 × 7-m straight
sections of the 8-walk) were low pass ﬁltered (zero phase
fourth order Butterworth with cut-off frequency of 25 Hz).

The gait events (heel strikes and toe-offs) were automatically
extracted using a custom algorithm based on foot velocity.30
Asymmetry ratio. Spatiotemporal gait measures of step length,
step time, swing time, and stance time (Supplementary
Methods 2) were evaluated for each foot separately. All
outliers deﬁned as intervals outside ±4 median absolute
deviation (MAD) away from the median were eliminated.
The number of outliers eliminated by this process across all
parameters and participant groups was 15 (maximum) out of
221 (average) walking steps. For each subject, we then determined which foot had the larger vs smaller amplitude (e.g.,
longer vs shorter mean step length) for evaluating the
asymmetry ratios31
Asymmetry
maximum amplitude  minimum amplitude
∗ 100
¼
maximum amplitude
Asymmetry ratio of zero percentage indicates perfect
symmetry.
Phase coordination index. Bilateral dyscoordination in left–
right stepping phase was analyzed using the phase coordination index (PCI,32 Supplementary Methods 2). Lower PCI
values reﬂect a more accurate and consistent left–right
stepping phase generation.
Walking speed was additionally evaluated for all
individuals.

4

Statistical Analyses
For the comparison of demographic characteristics, t-tests and
chi-square tests were performed. Signiﬁcance was set at .01.
Clinical scores. Changes in the overall clinical scores were
computed as: [(Pre-surgery scores – Post-surgery scores)/Presurgery scores] × 100%. The Wilcoxon signed-rank test was
used to determine difference between the scores. Signiﬁcance
was set at P < .05. In addition, we tested whether the overall
differences met the criteria of clinical relevance set by the
minimal clinically important difference (MCID) thresholds
(Part I: 2.64 points,33 Part II: 3.05 points,33 Part III: 3.25
points,34 and Part IV: .9 points35).
Changes to individual items (and composite of sub-items)
were computed as mean differences [95% conﬁdence interval]. The procedure for obtaining bootstrap conﬁdence interval36 is detailed in Supplementary Methods 3. These
changes are not tested for signiﬁcance because of large
number of ties (no differences) in the data.
Gait characteristics. For the investigation of the neuromodulatory effects of DBS treatment on asymmetry and
dyscoordination, effect sizes (ES) (Hedges’ g36) with 95%
conﬁdence interval CI (Supplementary Methods 3) were
calculated using bootstrap resampling. The 95% CI on the
effect size gives a measure of precision and conﬁdence about
our estimate and is not sensitive to the distribution of observations or underlying populations.37 The rationale for
including a control group is to demonstrate the importance of
the direction of intervention effects (e.g., modiﬁcation in
asymmetry with respect to physiological asymmetry observed in asymptomatic controls without PD). The P-value of
the two-sided permutation t-test is reported in case of signiﬁcant differences (Supplementary Methods 3). Signiﬁcance
was set at P < .05.
All analyses were conducted in MATLAB (v2019a, The
Mathworks Inc., USA) and R (version 1.2.5033, The R
Foundation for Statistical Computing, Austria).

Results
Patient and Demographic Data
The overall subject dropout rate was 13.5% (5 PwPD). One
participant dropped out before surgery and 4 participants dropped
out after surgery as presented in Supplementary Figure 1. There
were signiﬁcant differences (P < .01) in the age, proportion of
male/female, height, and weight between PwPD and
asymptomatic controls. Conversely, the 2 PwPD subtypes
groups did not signiﬁcantly differ in those characteristics.

Clinical Characteristics
MDS-UPDRS data were collected at a mean of 2.6 (SD 1.6)
and 5.7 (.7) months before and after surgery, respectively. In
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the standardized evaluation of motor symptoms of the disease, MDS UPDRS-III score improved from a baseline
OFF medication value of 39.97 (12.5) by 58% at 6 months
after surgery (Table 2). In comparison to the baseline OFF
medication at 6 months, the scores for UPDRS-I improved
by 27% (range: 100 to 89), those for UPDRS-II improved
by 46% (range: 0 to 90), and those for UPDRS-IV improved by 70% (0 to 100). All these functional improvements were signiﬁcant (P < .001) and exceeded the MCID
thresholds. Postoperatively, the levodopa equivalent daily
dosage also reduced signiﬁcantly (P < .001) from 1118.8
(511.55) mg at baseline to 365.31 (219.86) mg at 6 months
after surgery (Table 2).
A subgroup analysis was performed on MDS-UPDRS III
items that address clinical subtypes. The average MDSUPDRS TD/PIGD ratio for TD group was 3.28 (1.34) and
for PIGD group .33 (.29). The mean difference [95% CI]
between the groups was 2.95 [2.32, 3.79]. None of the study
participants belonged to the indeterminate subtype. The
composite scores for tremor improved by 3.91 [2.41, 5.47],
and those for posture and gait improved by 1.19 [.59, 2.38],
both near to 50% group-level improvement. MDS-UPDRS
Asymmetry: The difference between left and right MDSUPDRS III motor subscores was 2.29 (7.59) in PwPD, 4.23
(8.69) in the TD group and .89 (6.32) in the PIGD group.

Gait Characteristics PwPD
PwPD had higher asymmetry ratios (highest effect size
reported for step length asymmetry, ES [CI]: .56 [.06, 1.03],
P < .05) and higher PCI (.81 [.3, 1.26], P < .05) before
surgery compared to the asymptomatic control group
(Supplementary Table 3).
Increase in step time asymmetry (.27 [-.13, .73]) and PCI
(.29 [-.08, .67]) was observed post-surgery relative to presurgical status in PwPD. Differences in all other gait characteristics between pre- and post-surgery were negligible
(Table 3).

Gait Characteristics Clinical Subtypes
Between subtypes. The magnitude of difference between the
TD and PIGD subtypes was larger for PCI and walking speed
(both ES’s > .50) before surgery. The differences between the
subtypes increased post-surgery relative to pre-surgical status
in all the gait characteristics (notably step time asymmetry .40
[-.33, .97] to .69 [-.03, 1.33] and PCI .60 [-.10, 1.13] to .78
[.06, 1.35], P < .05) except walking speed (.55 [-1.27, 0.22]
to .32 [-.98, 0.40]), Table 4.
Within subtypes. Step time asymmetry (.38 [-.06, .90]) and
PCI (.39 [-.04, .84]) increased in the PIGD group following
surgery. Differences in all other gait characteristics within
subtypes, between pre- and post-surgery were negligible
(Table 4).
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Table 2. Effect of Bilateral Stimulation of the Subthalamic Nucleus on MDS-UPDRS scores.
PwPD Pre-DBS
OFF Med

PwPD Pre-DBS
ON Med

PwPD Post-DBS
ON Med*

PwPD Pre-DBS OFF Med vs PwPD
Post-DBS ON Med*

MDS-UPDRS I
MDS-UPDRS II
MDS-UPDRS III
MDS-UPDRS IV
Levodopa equivalent daily dose
(mg/day)

10.13 (4.32)
13.44 (4.65)
39.97 (12.5)
7 (3.30)
-

Overall scores
19.3 (7.4)
1118.8 (511.55)

6.34 (2.70)
7.38 (3.90)
16.5 (7.7)
1.81 (2.26)
365.31 (219.86)

26. 86 (36.50)†
46.09 (23.10)†
57.53 (15.68)†
70.02 (32.23)†
64.50 (19.79)†

Sub-items 3.15a till 3.18, sum of
tremor (0–40)
Sub-items 3.10 till 3.12, sum of
PIGD (0–12)
2.10. Item tremor (0–4)
2.12. Item walking and balance (0–4)
2.13. Item freezing (0–4)
3.10. Item gait (0–4)
3.11. Item freezing (0–4)
3.12. Item postural stability (0–4)

7.56 (6.32)

Characteristic

Subscores and individual items
2.06 (3.39)
3.65 (3.50)

3.91 [2.41, 5.47]

2.41 (2.23)

1.06 (.83)

1.16 (1.50)

1.19 [.59, 2.38]

1.19 (.95)
1.13 (.48)
.66 (.85)
1.38 (.70)
.41 (.82)
.63 (.96)

.78 (.41)
.09 (.29)
.19 (.46)

.81
.84
.23
.68
.23
.29

.38
.28
.44
.66
.19
.34

(.74)
(.63)
(.49)
(.53)
(.61)
(.73)

[.13, .59]
[.13, .41]
[.13, .72]
[.44, .97]
[-.03, .56]
[.00, .72]

Clinical subtypes

Characteristic

PwPD Pre-DBS OFF
Med

PwPD Pre-DBS ON PwPD Post-DBS ON PwPD Pre-DBS OFF Med vs
Med
Med*
PwPD Post-DBS ON Med*

TD

PIGD

TD

PIGD

3.37
(3.47)
3.21
(2.57)

3.54
(4.53)
.77 (.42)

1.05
6.38
(1.67)
(3.43)
1.26 (.96) .77 (.89)

Sub-items 3.15a till 3.18. Sum of tremor 13.69
(0–40)
(4.18)
Sub-items 3.10 till 3.12. Sum of PIGD 1.23 (.58)
(0–12)

TD

PIGD

TD

PIGD

1.67
(1.80)
1.50
(1.77)

7.31 [5.62,
1.58 [.16,
9.54]
3.16]
.46 [-.31, .77] 1.68 [.79,
3.58]

Values expressed as mean (standard deviation).
*3 patients were in OFF medication state.
Change on MDS-UPDRS I to IV and levodopa equivalent daily dose are provided as mean (standard deviation) percentages. †P < .001; The P values reported
denote level of statistical signiﬁcant difference.
Changes on subscores, individual items, clinical subtypes are provided as mean differences [conﬁdence intervals].; Abbreviations: MDS-UPDRS, Movement
Disorder Society-Uniﬁed Parkinson’s Disease Rating Scale; PwPD,Patients with Parkinson’s disease; DBS, deep brain stimulation; TD, tremor dominant; PIGD,
postural instability and gait disorder.

In comparison to asymptomatic controls without PD, the
PIGD group registered signiﬁcant differences (P < .05) in the
following gait characteristics: step length asymmetry (.67
[-1.35,-.06]), step time asymmetry (.62 [-1.23,-.03]), and
PCI (1.08 [-1.64,-.42]) before surgery; step length asymmetry (.60 [-1.3, 0.01]), step time asymmetry (1.1 [-1.8,.42]), swing time asymmetry (.63 [-1.2,-.03]), stance time
asymmetry (.66 [-1.22,-.03]), and PCI (1.45 [-2.14,.75]) after surgery, Supplementary Table 3.

Discussion
Our exploratory study was designed to investigate the therapeutic effects of STN-DBS on gait asymmetry, dyscoordination, and walking speed 6 months post-surgery in PwPD.
Our results revealed the following: (1) As anticipated, PwPD

showed signiﬁcant clinical motor and non-motor improvement (MDS-UPDRS I through IV) after surgery,
together with a signiﬁcant reduction in dopaminergic
medication. (2) STN-DBS induced increase in step time
asymmetry and dyscoordination at follow-up. (3) Group
differences in baseline (before surgery) gait characteristics
are critical to discretize treatment planning, as indicated by
higher level of asymmetry, dyscoordination, and slower
walking speed in PIGD patients compared to the TD group.
Six-month increase in step time asymmetry and dyscoordination after surgery were higher in the PIGD group than
the TD group. Collectively, our study documents novel
aspects of functional differences in DBS treatment response guided by different motor subtypes with an eye
toward their relevance as objective biomarkers for use in
clinical settings.

6

Neurorehabilitation and Neural Repair 0(0)

Table 3. Effect of Bilateral Stimulation of the Subthalamic Nucleus on Gait Characteristics.
Characteristic
Asymmetry (%)
Step length
Step time
Swing time
Stance time
Dyscoordination (%)
PCI
Other gait measures
Walking Speed (cm/s)

PwPD Pre-DBS

PwPD Post-DBS

Healthy Controls

PwPD Pre-DBS vs PwPD Post-DBS

4.81
2.79
3.35
2.06

4.60
3.48
3.76
2.36

2.90
1.93
2.36
1.48

.05 [-.38, 0.32]
.27 [-.13, 0.73]
.10 [-.24, 0.49]
.11 [-.21, 0.51]

(4.19)
(2.32)
(4.19)
(2.66)

(3.50)
(2.61)
(4.07)
(2.72)

(2.69)
(1.70)
(1.92)
(1.20)

3.06 (1.06)

3.42 (1.41)

2.29 (.82)

.29 [-.08, 0.67]

117.09 (18.21)

119.11 (18.42)

120.95 (14.31)

.11 [-.11, 0.36]

Values expressed as mean (standard deviation).
Changes are provided as Hedges’ g effect size [95% conﬁdence interval]. That is to say, we can be 95% conﬁdent that the interval contains the true effect size.
If PwPD post-DBS registered larger magnitude of gait parameter in comparison to PwPD pre-DBS, the effect size is positive. Abbreviations: PCI, phase
coordination index; PwPD, patients with Parkinson’s disease; DBS, deep brain stimulation.
Please refer to Supplementary Table 3 for comparison against healthy controls.

Mild asymmetry in the walking patterns of asymptomatic
healthy individuals is quite common and plausibly functional.38 It is likely that such asymmetrical patterns during
walking persist as a result of the natural hemispheric functional speciﬁcities in the relative contribution of lower limbs
to propulsion (facilitate forward progression) and braking
(facilitate postural stabilization).38,39 In PwPD, asymmetry
markedly increases and has been directly related to poor
walking ability40,41 and adverse episodes such as FOG and
falls.16,42,43 The underlying pathophysiology leading to these
deﬁcits are multifactorial and have not yet been completely
understood. We may conceivably (albeit inconclusively)
attribute these deﬁcits to a bilateral but asymmetric neurodegenerative process that is characteristic of PD (asymmetrical motor function may persist over the years despite
bilateral disease progression44). Patients with PD (PwPD)
also appear to have reduced corpus callosum function, which
interferes with the normal bilateral coordination of limb
movements during walking.45 Although, there is only a
marginal agreement on the underpinnings of asymmetrical
motor and gait symptoms in PwPD, such features are starting
to provide essential movement biomarkers to guide diagnosis
and treatment.19,21
DBS treatment seems like an ideal approach for improving
asymmetry and dyscoordination of walking as it provides the
opportunity to modify stimulation parameters for each
hemisphere independently. However, we observed that STNDBS increased gait asymmetry and dyscoordination, when
comparing pre vs post-surgery. Similar to our ﬁndings, one
recent study11 also reported increased gait asymmetry 6month post-DBS compared to preoperative assessment.
These results differ from a previous work that demonstrated a
signiﬁcant improvement in gait asymmetry in response to
STN-DBS treatment.16 The difference in results can be attributed primarily to the study design (Johnsen and colleagues
only presented postoperative DBS OFF vs ON gait outcomes

in OFF medication state). Postoperative microlesion effects
(e.g., some permanent lesion related to electrode insertion)
may introduce bias46 and does not allow us to equate and
compare the pre-DBS state (of our study) to OFF DBS state
(in Johnsen et al 2009). Also relevant, however, is the definition of gait asymmetry (Johnsen and colleagues looked at
spatial distance between heel to projected center of mass16).
The increase in asymmetry and dyscoordination that we are
reporting is calculated based on temporal metrics (step time
asymmetry and PCI).
With speciﬁc interest to the observation of increased step
time asymmetry (and PCI) and negligible effects on step
length asymmetry, our study plausibly suggests a differential
effect of STN-DBS on the temporal deﬁcit or a possible
adaptation of temporal characteristics to allow regulation of
spatial characteristics. This coincides with other studies
showing that STN-DBS increases walking speed in patients
by spatial (increasing step length) rather than temporal
changes (increasing cadence or step time).2,17 There is surmounting evidence indicating that cortical centers are responsible for movement initiation, while “ongoing”
movements are steadily regulated via subcortical regions
within the basal ganglia and the brain stem.47,48 These regions
are responsible for providing internal cues to cortical and
subcortical regions, for example, the pre-motor and supplementary motor area, accounting for the regulation of spatial
parameters.49 In this regard, it is possible that the regulation
of temporal parameters is not under the inﬂuence of corticothalamo-basal ganglia circuitry.50 However, further research
is necessary to substantiate the notion that these parameters
(cadence and step length, but also asymmetry in step time and
length) may reﬂect distinct regulation but allow mutual
interactions.51
Gait impairments in PwPD, from the symptom onset to
their advanced stages, including response to treatments
(levodopa52 and DBS53), demonstrate patient as well as group

Values expressed as mean (standard deviation).
Changes are provided as Hedges’ g effect size [95% conﬁdence interval]. That is to say, we can be 95% conﬁdent that the interval contains the true effect size.
How to interpret TD pre vs PIGD pre: If PIGD pre registered larger magnitude of gait parameter in comparison to TD pre, the effect size is positive.
¥
P < .05; The P values of the two-sided permutation t-test.
Abbreviations. PCI, phase coordination index; PwPD, patients with Parkinson’s disease; DBS, deep brain stimulation; TD, tremor dominant; PIGD, postural instability and gait disorder.

.18 [-.11, 0.54]
.02 [-.34, 0.34]
123.14 (15.59) 112.96 (18.71) 122.77 (15.52) 116.60 (19.78) .55 [-1.27, .22]

.32 [-.98, .40]

.39 [-.04, 0.84]
.78 [.06, 1.35]
.60 [-.10, 1.13]
3.86 (1.52)
2.79 (.90)
3.32 (1.16)
2.67 (.73)

(3.85)
(2.52)
(4.37)
(2.90)
5.00
3.18
3.71
2.28
4.52
2.22
2.81
1.73

Asymmetry (%)
Step length
Step time
Swing time
Stance time
Dyscoordination (%)
PCI
Other gait measures
Walking Speed (cm/s)

Characteristic

TD

(4.64)
(1.84)
(3.85)
(2.23)

PIGD

(2.17)
(2.06)
(2.85)
(1.46)

(4.15)
(2.70)
(4.66)
(3.24)

.11
.40
.20
.20

[-.74,
[-.33,
[-.68,
[-.63,

.80]
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.17
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.28
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[-.51,
[-.03,
[-.45,
[-.28,

.75]
1.33]
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¥

.13 [-.76, 0.96]

4.85
4.21
4.25
2.82
4.24
2.41
3.05
1.70

.04 [-.46, 0.39]
.38 [-.06, 0.90]
.11 [-.29, 0.67]
.17 [-.22, 0.69]

TD Pre vs TD Post PIGD Pre vs Post
TD Pre vs PIGD Pre TD Post vs PIGD Post
PIGD
TD

.07 [-.60, 0.65]
.09 [-.83, 1.0]
.06 [-.57, 0.67]
.01 [-.64, 0.59]

Within Subtypes
Between Subtypes
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PwPD Post-DBS
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(TD vs PIGD) speciﬁc traits. In our study, the TD group had
comparatively less impaired gait to the overall group of
patients both before and after surgery. On the other hand,
PIGD patients demonstrated a more pronounced increase
(more than the longitudinal changes due to disease progression reported previously in PwPD54) in asymmetry and
dyscoordination compared to the TD group due to DBS,
consistent with a previous clinical investigation.53 Natural
prognosis (PIGD may naturally progress more quickly in
disease course55) and inadequate targeting of the STN sub
territories responsible for the manifestation of the PIGD
subtype56 likely underlie differences in treatment outcomes,
but future studies may shed light on these hypotheses.

Limitations
We note the following limitations in our study. First, the
demographic characteristics (age, sex distribution, height,
and weight) of the PwPD group were signiﬁcantly different
from asymptomatic controls group, but we did not factor this
in the estimation of effect sizes in the present study. A better
approach would be to use a statistical test that includes them
as covariates; however, this may require large sample sizes
which remain to be explored in future analyses. Second, the lack
of information about fall history of the participants limited our
ability to answer the question whether asymmetric and dyscoordinated gait is associated with increased fall risk after STNDBS in PwPD. Third, there were also limitations in the design of
the study (gait being a secondary outcome) that did not allow us
to replicate novel unilateral stimulation protocols suggested
toward improving gait asymmetry and dyscoordination in patients with Parkinson’s disease.23 Fourth, the non-randomized
and unblinded design might be another limitation of our study.
Last, the relatively small sample of female PwPD may have
limited our ability to conﬁrm previous observations57,58 of
gender-related factors for STN-DBS outcomes in PwPD.

Conclusion
The present ﬁndings show the efﬁcacy of DBS of the STN in
reducing motor symptoms and related clinical outcomes in
PwPD at 6 months after surgery. Despite clinical improvement, STN-DBS treatment altered temporal asymmetry and
dyscoordination of walking. In particular, PIGD patients
demonstrated a more pronounced decline in these gait
characteristics compared to the TD group.
STN is a complex subcortical motor network and regulate
a myriad of motor features required in daily life of PwPD.59
Current approaches to STN-DBS therapy are based on an
inadequate assessment of such features and thus hinder
providing any deﬁnitive recommendations about the therapy. Our study provides preliminary insights into the
mechanisms possibly regulating DBS outcomes for subtle,
yet important gait features like symmetry and coordination.
However, our ﬁndings ought to be validated in future
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randomized controlled trials prior to translating into clinical
rehabilitation settings.
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35. Makkos A, Kovács M, Pintér D, Janszky J, Kovács N. Minimal
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